Caribou Biosciences, Inc. Shareholders' Equity
Caribou Biosciences, Inc. (CRBU) had Shareholders' Equity of $98.10 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $98.10M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $102.02M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $122.17M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $141.84M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $98.10M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $102.02M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $122.17M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $141.84M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $166.13M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $217.22M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $252.95M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $281.20M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $310.46M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $343.29M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $368.40M 10-K · filed 2026-03-05 |
| 2023-09-30 | $398.27M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $269.46M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $278.27M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $300.87M 10-K · filed 2025-03-10 |
| 2022-09-30 | $324.11M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $347.89M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $371.80M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $387.82M 10-K · filed 2024-03-11 |
| 2021-09-30 | $404.40M 10-Q · filed 2022-11-08 |
| 2021-06-30 | -$47.69M 10-Q · filed 2022-11-08 |
| 2021-03-31 | -$35.69M 10-Q · filed 2022-11-08 |
| 2020-12-31 | -$23.44M 10-K · filed 2023-03-09 |
| 2020-09-30 | -$11.21M 10-Q · filed 2021-11-09 |
| 2020-06-30 | -$3.67M 10-Q · filed 2021-11-09 |
| 2020-03-31 | -$2.10M 10-Q · filed 2021-11-09 |
| 2019-12-31 | $7.46M 10-K · filed 2022-03-21 |
| 2018-12-31 | $29.95M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |